Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HROW

HROW - Harrow Health Inc Stock Price, Fair Value and News

$42.61-0.37 (-0.86%)
Market Closed

37/100

HROW

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

37/100

HROW

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$35.58

Target 3M

$42.02

Target 6M

$39.71

HROW Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HROW Price Action

Last 7 days

-9.6%

Last 30 days

-16.1%

Last 90 days

13.5%

Trailing 12 Months

30.3%

HROW RSI Chart

HROW Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HROW Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-316.39

Price/Sales (Trailing)

6.31

EV/EBITDA

44.55

Price/Free Cashflow

95.23

HROW Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$35.58

Target 3M

$42.02

Target 6M

$39.71

HROW Fundamentals

HROW Revenue

Revenue (TTM)

250.0M

Rev. Growth (Yr)

45.44%

Rev. Growth (Qtr)

12.39%

HROW Earnings

Earnings (TTM)

-5.0M

Earnings Growth (Yr)

124.17%

Earnings Growth (Qtr)

-79.58%

HROW Profitability

EBT Margin

3.23%

Return on Equity

-10.61%

Return on Assets

-1.37%

Free Cashflow Yield

1.05%

HROW Investor Care

Shares Dilution (1Y)

3.99%

Diluted EPS (TTM)

-0.15

HROW Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025212.9M227.7M250.0M0
2024138.7M154.1M169.1M199.6M
202392.6M102.7M114.2M130.2M
202279.2M84.3M88.5M88.6M
202152.5M62.6M66.9M72.5M
202050.7M45.2M46.9M48.9M
201944.8M47.9M49.9M51.2M
201830.4M34.1M37.7M41.4M
2017022.4M24.6M26.8M
2016013.1M16.0M19.1M
20153.2M4.5M6.8M9.7M
20142.7M2.3M2.0M1.7M
20133.7M3.3M3.0M0
20120004.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Harrow Health Inc

HROW
Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITEharrowinc.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES217

Harrow Health Inc Frequently Asked Questions

HROW is the stock ticker symbol of Harrow Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Harrow Health Inc is 1.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HROW's fair value in chart for subscribers.

The fair value guage provides a quick view whether HROW is over valued or under valued. Whether Harrow Health Inc is cheap or expensive depends on the assumptions which impact Harrow Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HROW.

As of Wed Jan 28 2026, HROW's PE ratio (Price to Earnings) is -316.39 and Price to Sales (PS) ratio is 6.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HROW PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Harrow Health Inc has provided 0.217 (multiply by 100 for percentage) rate of return.